MMMuhammed Hamza Muslumanoglu

Muhammed Hamza Muslumanoglu

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Muhammed Hamza Muslumanoglu has a total of 10 co-authors. Here are the top co-authors by number of shared publications:

  • Ahmet Uludag

    Department of Medical Genetics, Eskisehir Osmangazi University School of Medicine, Eskisehir, Turkey

    1 shared publication
  • Derya Uzun

    Department of Medical Genetics, Eskisehir Osmangazi University School of Medicine, Eskisehir, Turkey

    1 shared publication
  • Emre Tepeli

    Department of Medical Genetics, Eskisehir Osmangazi University School of Medicine, Eskisehir, Turkey

    1 shared publication
  • Engin Atlı

    Department of Medical Genetics, Eskisehir Osmangazi University School of Medicine, Eskisehir, Turkey

    1 shared publication
  • Kemal M. Canturk

    Department of Medical Genetics, Eskisehir Osmangazi University School of Medicine, Eskisehir, Turkey

    1 shared publication
  • Mehmet Turgut

    Department of Urology, Eskisehir Osmangazi University School of Medicine, Eskisehir, Turkey

    1 shared publication

Latest Publications

  • Open Access

    Investigation of the cytotoxic, anti-proliferative and anti-angiogenic effects of Toluhydroquinone on Caco-2 cell line

    by Mine Kucak, Ummuhan Demir, Muhammed Hamza Muslumanoglu

    Colorectal cancer is one of the most common types of cancer in the world. The treatment options for colorectal carcinoma generally consist of surgery, radiotherapy and chemotherapy. The drug resistance to chemotherapy agents used in the current cancer treatment has brought about the finding of new drug molecules from some plant and aquatic species in the treatment approaches. Some species of aquatic biota create novel biomolecules as potential drugs for cancer and other diseases. Toluhydroquinone belongs to these groups of biomolecules and it shows anti-oxidative, anti-inflammatory and anti-angiogenic properties. In this study, we tested the cytotoxic and anti-angiogenic effects of Toluhydroquinone on Caco-2(Human colorectal carcinoma cell line) cells. It was observed that the amount of closure of the wound space, colony forming ability (in vitro cell survivability) and formation of tubule-like structures in matrigel decreased in comparison to the control group. As a result of this study, Toluhydroquinone has cytotoxic, anti-proliferative and anti-angiogenic properties on the Caco-2 cell line.


  • The Analysis of the Relationship Between A1298C and C677T Polymorphisms of the MTHFR Gene with Prostate Cancer in Eskisehir Population

    by Muhammed H. Muslumanoglu, Emre Tepeli, Selma Demir, Ahmet Uludag, Derya Uzun, Engin Atlı, Kemal M. Canturk, Muhsin Ozdemir, Mehmet Turgut

    Prostate cancer is the most common cause of cancer deaths in men and is a major health problem worldwide. Methylene tetrahydrofolate reductase (MTHFR) plays an important role for folate metabolism and is also an important source for DNA methylation and DNA synthesis (nucleotide synthesis). The objective of this study was to investigate the relationship between the A1298C and C677T polymorphisms of the MTHFR gene and prostate cancer in the Turkish population. In our study, 93 prostate cancer patients between the ages of 50–89 and a control group of 166 benign prostate hyperplasia patients were evaluated. C677T and A1298C polymorphism ratios were compared among these two groups, and an analysis was made to see if there is a statistically meaningful difference. In this study, it has been observed that C677T polymorphism of the MTHFR gene produces no statistically significant difference for T allele frequency and the genotype frequency in prostate cancer patients and male controls with benign prostate hyperplasia not having prostate cancer, whereas it has been observed that A1298C polymorphism produces a statistically significant difference for C allele frequency in prostate cancer patients and controls and that it also produces a statistically marginal significance for genotype frequencies.